vs

Side-by-side financial comparison of Future Vision II Acquisition Corp. (FVN) and Pelthos Therapeutics Inc. (PTHS). Click either name above to swap in a different company.

Future Vision II Acquisition Corp. is the larger business by last-quarter revenue ($584.4K vs $294.0K, roughly 2.0× Pelthos Therapeutics Inc.). Future Vision II Acquisition Corp. runs the higher net margin — 86.8% vs -5523.1%, a 5609.9% gap on every dollar of revenue.

Future Vision II Acquisition Corp is a special purpose acquisition company formed to pursue mergers, asset acquisitions, or business combinations with high-growth enterprises. It targets technology, consumer, and sustainable industry segments across North American and Asia-Pacific markets to drive long-term shareholder value.

Pelthos Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for rare metabolic and endocrine diseases with significant unmet medical needs. It operates primarily across North America and Europe, with a pipeline of novel drug candidates addressing underserved patient populations.

FVN vs PTHS — Head-to-Head

Bigger by revenue
FVN
FVN
2.0× larger
FVN
$584.4K
$294.0K
PTHS
Higher net margin
FVN
FVN
5609.9% more per $
FVN
86.8%
-5523.1%
PTHS

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FVN
FVN
PTHS
PTHS
Revenue
$584.4K
$294.0K
Net Profit
$507.0K
$-16.2M
Gross Margin
-687.8%
Operating Margin
-14.4%
-5225.2%
Net Margin
86.8%
-5523.1%
Revenue YoY
Net Profit YoY
-858.0%
EPS (diluted)
$-5.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FVN
FVN
PTHS
PTHS
Q4 25
$584.4K
Q3 25
$618.7K
$294.0K
Q2 25
$614.4K
Q1 25
$612.4K
Q3 24
$147.8K
Net Profit
FVN
FVN
PTHS
PTHS
Q4 25
$507.0K
Q3 25
$557.2K
$-16.2M
Q2 25
$551.9K
Q1 25
$454.3K
Q3 24
$141.9K
Gross Margin
FVN
FVN
PTHS
PTHS
Q4 25
Q3 25
-687.8%
Q2 25
Q1 25
Q3 24
Operating Margin
FVN
FVN
PTHS
PTHS
Q4 25
-14.4%
Q3 25
-11.2%
-5225.2%
Q2 25
-11.5%
Q1 25
-27.3%
Q3 24
-4.5%
Net Margin
FVN
FVN
PTHS
PTHS
Q4 25
86.8%
Q3 25
90.1%
-5523.1%
Q2 25
89.8%
Q1 25
74.2%
Q3 24
96.0%
EPS (diluted)
FVN
FVN
PTHS
PTHS
Q4 25
Q3 25
$-5.30
Q2 25
Q1 25
Q3 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FVN
FVN
PTHS
PTHS
Cash + ST InvestmentsLiquidity on hand
$61.0M
$14.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.8M
$58.3M
Total Assets
$62.1M
$126.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FVN
FVN
PTHS
PTHS
Q4 25
$61.0M
Q3 25
$14.2M
Q2 25
Q1 25
Q3 24
$1.3M
Stockholders' Equity
FVN
FVN
PTHS
PTHS
Q4 25
$1.8M
Q3 25
$3.1M
$58.3M
Q2 25
$4.3M
Q1 25
$7.0M
Q3 24
$6.7M
Total Assets
FVN
FVN
PTHS
PTHS
Q4 25
$62.1M
Q3 25
$61.6M
$126.4M
Q2 25
$61.0M
Q1 25
$60.4M
Q3 24
$59.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FVN
FVN
PTHS
PTHS
Operating Cash FlowLast quarter
$-99.4K
$-15.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.20×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FVN
FVN
PTHS
PTHS
Q4 25
$-99.4K
Q3 25
$-7.1K
$-15.3M
Q2 25
$-11.2K
Q1 25
$-190.1K
Q3 24
Cash Conversion
FVN
FVN
PTHS
PTHS
Q4 25
-0.20×
Q3 25
-0.01×
Q2 25
-0.02×
Q1 25
-0.42×
Q3 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons